



Pyruvate Kinase type M2 (PKM2) Promotes Cancer Cell Metastasis Through Interacting with TWIST-1

Journal of Health Disparities Research and Practice

Volume 9
Issue 5 *Special Issue - NIDDK STEP UP*

Article 69

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2016

Pyruvate Kinase type M2 (PKM2) Promotes Cancer Cell Metastasis Through Interacting with TWIST-1

Odunayo Durojaye

Hailun Wang, PhD , *Vanderbilt University*

Follow this and additional works at: <https://digitalscholarship.unlv.edu/jhdrp>



Part of the [Bilingual, Multilingual, and Multicultural Education Commons](#), [Community College Leadership](#)

[Commons](#), [Higher Education Commons](#), [Immune System Diseases Commons](#), [Public Health Commons](#), [Translational Medical Research Commons](#), and the [Virus Diseases Commons](#)

Recommended Citation

Durojaye, Odunayo and Wang, PhD, Hailun (2016) "Pyruvate Kinase type M2 (PKM2) Promotes Cancer Cell Metastasis Through Interacting with TWIST-1," *Journal of Health Disparities Research and Practice*: Vol. 9: Iss. 5, Article 69.

Available at: <https://digitalscholarship.unlv.edu/jhdrp/vol9/iss5/69>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Journal of Health Disparities Research and Practice by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

Pyruvate Kinase type M2 (PKM2) Promotes Cancer Cell Metastasis Through Interacting with TWIST-1

Abstract

Tumor growth and metastasis are key processes in understanding tumor progression and cancer fatality. Pyruvate Kinase type M2 (PKM2) is a key enzyme that regulates glucose metabolism in cells in a biochemical pathway known as glycolysis. Glycolysis provides cells with energy (ATP) and building blocks (nucleic acids, amino acids and lipids) that are critical for cell survival and proliferation. Therefore, cancer cells rely heavily on this metabolic process to survive and thrive. PKM2 is overexpressed in most cancers, and is highly involved with cancer cell growth. Several recent studies have further revealed a potential role of PKM2 in regulating epithelial-mesenchymal transition (EMT[PTT1]) and cancer cell metastasis. The aim of this study is to study the mechanisms by which PKM2 regulates EMT and promotes cancer metastasis.

In our previous studies, we identified a potential Pkm2 protein interacting partner - Twist1 protein. Twist1 is a key transcription factor that regulates EMT and cancer metastasis. It has been reported that the nuclear translocation of PKM2 can regulate transcriptional activity of several other transcription factors. Therefore, the interaction between Pkm2 and Twist1 can potentially enhance Twist1 transcriptional activity in EMT and metastasis.

In the current study, we are knocking out the *PKM2* gene in cancer and immortalized primary cell lines by using the CRISPR-Cas9 system. We will study the changes in cell proliferation and migration after knocking out *PKM2*. Later, we will overexpress TWIST1 in these cells by using plasmid transfection or viral infection and study whether TWIST1 can restore the cells to their original phenotype.

Keywords

Metastasis; EMT



Journal of Health Disparities Research and Practice
Volume 9, Special Edition 1, Summer 2016, pp. 102-103
© 2011 Center for Health Disparities Research
School of Community Health Sciences
University of Nevada, Las Vegas

Pyruvate Kinase type M2 (PKM2) Promotes Cancer Cell Metastasis Through Interacting with TWIST-1

Odunayo Durojaye

Hailun Wang, PhD, Vanderbilt University

Coordinating Center: Stanford University

ABSTRACT

Tumor growth and metastasis are key processes in understanding tumor progression and cancer fatality. Pyruvate Kinase type M2 (PKM2) is a key enzyme that regulates glucose metabolism in cells in a biochemical pathway known as glycolysis. Glycolysis provides cells with energy (ATP) and building blocks (nucleic acids, amino acids and lipids) that are critical for cell survival and proliferation. Therefore, cancer cells rely heavily on this metabolic process to survive and thrive. PKM2 is overexpressed in most cancers, and is highly involved with cancer cell growth. Several recent studies have further revealed a potential role of PKM2 in regulating epithelial-mesenchymal transition (EMT[PTT1]) and cancer cell metastasis. The aim of this study is to study the mechanisms by which PKM2 regulates EMT and promotes cancer metastasis.

In our previous studies, we identified a potential Pkm2 protein interacting partner - Twist1 protein. Twist1 is a key transcription factor that regulates EMT and cancer metastasis. It has been reported that the nuclear translocation of PKM2 can regulate transcriptional activity of several other transcription factors. Therefore, the interaction between Pkm2 and Twist1 can potentially enhance Twist1 transcriptional activity in EMT and metastasis.

In the current study, we are knocking out the *PKM2* gene in cancer and immortalized primary cell lines by using the CRISPR-Cas9 system. We will study the changes in cell proliferation and migration after knocking out *PKM2*. Later, we will overexpress TWIST1 in these cells by using plasmid transfection or viral infection and study whether TWIST1 can restore the cells to their original phenotype.

Key Words: Metastasis, EMT

103 Pyruvate Kinase type M2 (PKM2) Promotes Cancer Cell Metastasis Through Interacting with TWIST-1

Durojaye and Wang

ACKNOWLEDGEMENTS

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, Grant number: R25DK078382.